Agomab Announces Results of Annual General Meeting

Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM) held on Tuesday, May 26, 2026.

All items on the agenda were approved, including:

The voting result and all documents relating to the shareholders’ meeting are available on the Agomab investor relations website at https://ir.agomab.com/governance/shareholder-meetings.

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Contacts

Investors

Sofie Van Gijsel

VP of Investor Relations

E-mail: sofie.vangijsel@agomab.com

Phone: +1 781 296 1143

Media

Gretchen Schweitzer

Trophic Communications

E-mail: agomab@trophic.eu

Phone: +49 172 861 8540